Ofatumumab for the treatment of COVID-19-associated autoimmune encephalitis: A case report

IF 2.5 4区 医学 Q3 IMMUNOLOGY Journal of neuroimmunology Pub Date : 2025-03-19 DOI:10.1016/j.jneuroim.2025.578590
Zhuoran Wang , Xiaoping Du , Qiong Wang , Yating Zhang , Junhong Guo , Huifang Wang
{"title":"Ofatumumab for the treatment of COVID-19-associated autoimmune encephalitis: A case report","authors":"Zhuoran Wang ,&nbsp;Xiaoping Du ,&nbsp;Qiong Wang ,&nbsp;Yating Zhang ,&nbsp;Junhong Guo ,&nbsp;Huifang Wang","doi":"10.1016/j.jneuroim.2025.578590","DOIUrl":null,"url":null,"abstract":"<div><div>Autoimmune encephalitis is a rare but severe complication of Coronavirus disease 2019 (COVID-19) infection. Typically, treatment involves immunomodulatory approaches such as steroids, intravenous immunoglobulin (IVIG), or plasma exchange. While for some patients, the above treatment is not effective. Here, we report a case of COVID-19-associated encephalitis, who exhibited cognitive impairment, epileptic seizures, tachycardia, and diaphoresis, with cranial MRI findings resembling those seen in limbic encephalitis. Initially, the patient exhibited a suboptimal response to antiviral therapy, high-dose steroids, and IVIG treatment. Nevertheless, his clinical symptoms and cranial MRI abnormalities markedly improved following the administration of Ofatumumab. Administering Ofatumumab early in COVID-19-related autoimmune encephalitis may benefit patients more.</div></div>","PeriodicalId":16671,"journal":{"name":"Journal of neuroimmunology","volume":"403 ","pages":"Article 578590"},"PeriodicalIF":2.5000,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of neuroimmunology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0165572825000700","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Autoimmune encephalitis is a rare but severe complication of Coronavirus disease 2019 (COVID-19) infection. Typically, treatment involves immunomodulatory approaches such as steroids, intravenous immunoglobulin (IVIG), or plasma exchange. While for some patients, the above treatment is not effective. Here, we report a case of COVID-19-associated encephalitis, who exhibited cognitive impairment, epileptic seizures, tachycardia, and diaphoresis, with cranial MRI findings resembling those seen in limbic encephalitis. Initially, the patient exhibited a suboptimal response to antiviral therapy, high-dose steroids, and IVIG treatment. Nevertheless, his clinical symptoms and cranial MRI abnormalities markedly improved following the administration of Ofatumumab. Administering Ofatumumab early in COVID-19-related autoimmune encephalitis may benefit patients more.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Ofatumumab治疗covid -19相关自身免疫性脑炎1例报告
自身免疫性脑炎是2019冠状病毒病(COVID-19)感染的罕见但严重的并发症。通常,治疗包括免疫调节方法,如类固醇、静脉注射免疫球蛋白(IVIG)或血浆交换。而对于一些患者,上述治疗是无效的。在这里,我们报告了一例covid -19相关脑炎,其表现为认知障碍、癫痫发作、心动过速和出汗,其颅脑MRI结果与边缘脑炎相似。最初,患者对抗病毒治疗、大剂量类固醇和IVIG治疗反应不佳。然而,在给予Ofatumumab后,他的临床症状和颅MRI异常明显改善。在covid -19相关自身免疫性脑炎的早期使用Ofatumumab可能对患者更有益。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of neuroimmunology
Journal of neuroimmunology 医学-免疫学
CiteScore
6.10
自引率
3.00%
发文量
154
审稿时长
37 days
期刊介绍: The Journal of Neuroimmunology affords a forum for the publication of works applying immunologic methodology to the furtherance of the neurological sciences. Studies on all branches of the neurosciences, particularly fundamental and applied neurobiology, neurology, neuropathology, neurochemistry, neurovirology, neuroendocrinology, neuromuscular research, neuropharmacology and psychology, which involve either immunologic methodology (e.g. immunocytochemistry) or fundamental immunology (e.g. antibody and lymphocyte assays), are considered for publication.
期刊最新文献
Soluble c-Met correlates with NfL and GFAP levels in the CSF of patients with multiple sclerosis. The role of the QT interval in predicting functional prognosis in patients with acute ischemic stroke. Mechanistic insights into the role of nuclear receptor related-1 protein in Parkinson's disease. Rethinking rituximab in neuroimmunology: Real-world efficacy, cost-effectiveness, and long-term remission. Safety and efficacy of intrathecal rituximab in refractory neuroimmune disorders- a case series.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1